Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
64.26 USD | +0.28% | -2.89% | -20.68% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- This company will be of major interest to investors in search of a high dividend stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 176.38 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 3.54 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-20.68% | 79.83B | B- | ||
+40.73% | 734B | C+ | ||
+32.83% | 591B | B | ||
-6.30% | 350B | C+ | ||
+15.15% | 315B | B- | ||
+4.05% | 276B | C+ | ||
+15.00% | 238B | B+ | ||
+9.78% | 206B | B- | ||
-5.52% | 204B | A+ | ||
+6.17% | 161B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GILD Stock
- Ratings Gilead Sciences, Inc.